{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:22:10Z","timestamp":1780618930598,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diabetic Peripheral Neuropathic Pain (DPNP) is a chronic complication affecting nearly half of individuals with diabetes. While monotherapies like pregabalin, duloxetine, and nortriptyline are frequently used, combination regimens may offer enhanced efficacy. Comparative studies of pregabalin\u2013nortriptyline (PG-NT) and pregabalin\u2013duloxetine (PG-DLX), especially in Indian populations, remain limited. A retrospective\u2013prospective cohort study was conducted over five months at a tertiary care centre in South India. Sixty adults with DPNP, treated for at least two months with PG-NT or PG-DLX, were followed for nine weeks. Participants received either pregabalin\u2013nortriptyline (dosed 150\u2013300\u00a0mg\/day and 10\u201375\u00a0mg\/day, respectively) or pregabalin 150\u2013300\u00a0mg\/day with duloxetine 60\u00a0mg\/day, for nine weeks. Efficacy was assessed using the Visual Analogue Scale (VAS), Insomnia Severity Index (ISI), and Hospital Anxiety and Depression Scale (HADS). Adverse events were documented. Both regimens significantly reduced pain scores. PG-DLX showed greater reductions in VAS (-2.23 vs. -1.35), ISI (-2.87 vs. -1.14), and HADS-A (-2.00 vs. -1.41). PG-DLX also significantly improved HADS-D scores (-1.70;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), while PG-NT did not (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.076). Adverse events were mild but more frequent with PG-DLX (30% vs. 16.67%). Both combinations are effective for managing DPNP. However, PG-DLX demonstrated superior benefits in pain relief, sleep quality, and mood symptoms, with a modest increase in mild adverse events.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-27617-2","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:36:39Z","timestamp":1765964199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative cohort study of pregabalin nortriptyline and pregabalin duloxetine in the management of diabetic peripheral neuropathic pain"],"prefix":"10.1038","volume":"15","author":[{"given":"Prathyusha Chowdary","family":"Dasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Chandu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Bodala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Poojitha","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh Chandra","family":"Chundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Sai","family":"Nelluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeram","family":"Thiriveedhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetanya","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"18","key":"27617_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede, R. D. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70 (18), 1630\u20131635. https:\/\/doi.org\/10.1212\/01.wnl.0000282763.29778.59 (2008).","journal-title":"Neurology"},{"issue":"4","key":"27617_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2337\/diacare.28.4.956","volume":"28","author":"AJM Boulton","year":"2005","unstructured":"Boulton, A. J. M. et al. Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 28 (4), 956\u2013962. https:\/\/doi.org\/10.2337\/diacare.28.4.956 (2005).","journal-title":"Diabetes Care"},{"issue":"6","key":"27617_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","volume":"11","author":"BC Callaghan","year":"2012","unstructured":"Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L. & Feldman, E. L. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 11 (6), 521\u2013534. https:\/\/doi.org\/10.1016\/S1474-4422(12)70065-0 (2012).","journal-title":"Lancet Neurol."},{"issue":"8","key":"27617_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2011.138","volume":"7","author":"AM Vincent","year":"2011","unstructured":"Vincent, A. M., Callaghan, B. C., Smith, A. L. & Feldman, E. L. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 7 (8), 573\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2011.138 (2011).","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"27617_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.2040-1124.2010.00007.x","volume":"1","author":"NA Calcutt","year":"2010","unstructured":"Calcutt, N. A. Diabetic neuropathy: mechanisms and future treatment options. J. Diabetes Investig. 1 (1), 33\u201339. https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00007.x (2010).","journal-title":"J. Diabetes Investig"},{"issue":"11","key":"27617_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/nn942","volume":"5","author":"J Scholz","year":"2002","unstructured":"Scholz, J. & Woolf, C. J. Can we conquer pain? Nat. Neurosci. 5 (11), 1062\u20131067. https:\/\/doi.org\/10.1038\/nn942 (2002).","journal-title":"Nat. Neurosci."},{"issue":"3 Suppl","key":"27617_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin, R. H. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Mayo Clin. Proc. 85 (3 Suppl), S3\u2013S14. https:\/\/doi.org\/10.4065\/mcp.2009.0649 (2010).","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"27617_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0304-3959(99)00154-2","volume":"83","author":"SH Sindrup","year":"1999","unstructured":"Sindrup, S. H. & Jensen, T. S. Efficacy of Pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (3), 389\u2013400. https:\/\/doi.org\/10.1016\/S0304-3959(99)00154-2 (1999).","journal-title":"Pain"},{"issue":"2","key":"27617_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14 (2), 162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0 (2015).","journal-title":"Lancet Neurol."},{"issue":"Suppl 6","key":"27617_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.45106.x","volume":"45","author":"E Ben-Menachem","year":"2004","unstructured":"Ben-Menachem, E. Pregabalin Pharmacology and its relevance to clinical practice. Epilepsia 45 (Suppl 6), 13\u201318. https:\/\/doi.org\/10.1111\/j.0013-9580.2004.45106.x (2004).","journal-title":"Epilepsia"},{"issue":"7082","key":"27617_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/bmj.314.7082.763","volume":"314","author":"HJ McQuay","year":"1997","unstructured":"McQuay, H. J. & Moore, R. A. Antidepressants and chronic pain. BMJ 314 (7082), 763\u2013764. https:\/\/doi.org\/10.1136\/bmj.314.7082.763 (1997).","journal-title":"BMJ"},{"issue":"1\u20132","key":"27617_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.018","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein, D. J. et al. Duloxetine versus placebo in patients with painful diabetic peripheral neuropathy. Pain 116 (1\u20132), 109\u2013118. https:\/\/doi.org\/10.1016\/j.pain.2005.03.018 (2005).","journal-title":"Pain"},{"issue":"10338","key":"27617_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(22)00389-0","volume":"399","author":"S Tesfaye","year":"2022","unstructured":"Tesfaye, S. et al. Comparison of amitriptyline, duloxetine, and Pregabalin combinations for diabetic neuropathic pain (OPTION-DM): a double-blind, multicentre, crossover trial. Lancet 399 (10338), 1406\u20131416. https:\/\/doi.org\/10.1016\/S0140-6736(22)00389-0 (2022).","journal-title":"Lancet"},{"issue":"1","key":"27617_CR14","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.36076\/ppj.2021\/24\/E1","volume":"24","author":"MM Asrar","year":"2021","unstructured":"Asrar, M. M., Kumari, S., Sekhar, B. C. & Kumar, S. Relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy: a systematic review and bayesian network meta-analysis. Pain Physician. 24 (1), E1\u2013E14. https:\/\/doi.org\/10.36076\/ppj.2021\/24\/E1 (2021).","journal-title":"Pain Physician"},{"key":"27617_CR15","doi-asserted-by":"publisher","first-page":"CD007115","DOI":"10.1002\/14651858.CD007115.pub2","volume":"1","author":"MP Lunn","year":"2014","unstructured":"Lunn, M. P., Hughes, R. A. & Wiffen, P. J. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst. Rev. 1, CD007115. https:\/\/doi.org\/10.1002\/14651858.CD007115.pub2 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"27617_CR16","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.18203\/2319-2003.ijbcp20194445","volume":"8","author":"S Jha","year":"2019","unstructured":"Jha, S., Sahani, O. P., Shah, S. & Singh, M. Observational study of Pregabalin vs Duloxetine in diabetic peripheral neuropathic pain. Int. J. Basic. Clin. Pharmacol. 8 (11), 2291\u20132295. https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20194445 (2019).","journal-title":"Int. J. Basic. Clin. Pharmacol."},{"issue":"3","key":"27617_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmjspcare-2018-001522","volume":"8","author":"C O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan, C. Nortriptyline for neuropathic pain: better tolerated than amitriptyline? BMJ Support Palliat. Care. 8 (3), 382\u2013384. https:\/\/doi.org\/10.1136\/bmjspcare-2018-001522 (2018).","journal-title":"BMJ Support Palliat. Care"},{"issue":"9","key":"27617_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.ejpain.2009.10.003","volume":"14","author":"R Baron","year":"2010","unstructured":"Baron, R., T\u00f6lle, T. R., Gockel, U., Brosz, M. & Freynhagen, R. Importance of secondary symptoms in neuropathic pain: sleep, mood, and quality of life. Eur. J. Pain. 14 (9), 902\u2013907. https:\/\/doi.org\/10.1016\/j.ejpain.2009.10.003 (2010).","journal-title":"Eur. J. Pain"},{"issue":"1","key":"27617_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/0976-500X.94013","volume":"3","author":"DK Arulmozhi","year":"2012","unstructured":"Arulmozhi, D. K. & Veeranjaneyulu, A. Indian perspective on diabetic neuropathy treatments. J. Pharmacol. Pharmacother. 3 (1), 22\u201329. https:\/\/doi.org\/10.4103\/0976-500X.94013 (2012).","journal-title":"J. Pharmacol. Pharmacother"},{"issue":"10","key":"27617_CR20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/j.pain.0000000000001002","volume":"158","author":"JV Holbech","year":"2017","unstructured":"Holbech, J. V. & Finnerup, N. B. Combination pharmacotherapy for neuropathic pain: an evidence-based review. Pain 158 (10), 1888\u20131896. https:\/\/doi.org\/10.1097\/j.pain.0000000000001002 (2017).","journal-title":"Pain"},{"key":"27617_CR21","doi-asserted-by":"publisher","first-page":"CD007076","DOI":"10.1002\/14651858.CD007076.pub3","volume":"1","author":"S Derry","year":"2019","unstructured":"Derry, S., Bell, R. F., Straube, S., Cole, J. B. & Moore, R. A. Pregabalin for neuropathic pain in adults. Cochrane Database Syst. Rev. 1, CD007076. https:\/\/doi.org\/10.1002\/14651858.CD007076.pub3 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"27617_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11892-019-1243-3","volume":"19","author":"CW Hicks","year":"2019","unstructured":"Hicks, C. W. & Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab Rep. 19 (12), 86. https:\/\/doi.org\/10.1007\/s11892-019-1243-3 (2019).","journal-title":"Curr. Diab Rep."},{"issue":"1","key":"27617_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.18203\/2349-3933.ijam20170387","volume":"4","author":"S Gogia","year":"2017","unstructured":"Gogia, S., Thakur, K. & Kaur, M. A study of clinical profile of painful diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Int. J. Adv. Med. 4 (1), 121\u2013124. https:\/\/doi.org\/10.18203\/2349-3933.ijam20170387 (2017).","journal-title":"Int. J. Adv. Med."},{"issue":"4","key":"27617_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13410-020-00844-1","volume":"40","author":"R Cynthra","year":"2020","unstructured":"Cynthra, R., Chacko, E. C., Sen, A. & Thomas, N. Clinical and electrophysiological profile of diabetic peripheral neuropathy in Southern India. Int. J. Diabetes Dev. Ctries. 40 (4), 475\u2013480. https:\/\/doi.org\/10.1007\/s13410-020-00844-1 (2020).","journal-title":"Int. J. Diabetes Dev. Ctries."},{"issue":"5","key":"27617_CR25","first-page":"529","volume":"16","author":"M Bayani","year":"2011","unstructured":"Bayani, M., Tabrizi, A., Abolhasani Foroughi, A. & Bayani, M. Comparison of Duloxetine and Pregabalin in treatment of painful diabetic peripheral neuropathy: a double-blind, randomized clinical trial. J. Res. Med. Sci. 16 (5), 529\u2013536 (2011).","journal-title":"J. Res. Med. Sci."},{"key":"27617_CR26","doi-asserted-by":"publisher","first-page":"e28683","DOI":"10.7759\/cureus.28683","volume":"14","author":"I Shah","year":"2022","unstructured":"Shah, I. et al. A prospective observational study comparing the efficacy and safety of Duloxetine and Pregabalin in diabetic peripheral neuropathic pain. Cureus 14, e28683. https:\/\/doi.org\/10.7759\/cureus.28683 (2022).","journal-title":"Cureus"},{"key":"27617_CR27","doi-asserted-by":"publisher","first-page":"4084420","DOI":"10.1155\/2022\/4084420","volume":"2022","author":"L Jiang","year":"2022","unstructured":"Jiang, L., Xiong, Y. & Cui, J. Comparison of the efficacy and safety of Duloxetine and Gabapentin in diabetic peripheral neuropathic pain: a meta-analysis. Contrast Media Mol. Imaging. 2022, 4084420. https:\/\/doi.org\/10.1155\/2022\/4084420 (2022).","journal-title":"Contrast Media Mol. Imaging"},{"key":"27617_CR28","doi-asserted-by":"publisher","unstructured":"Ball, S. G., Desaiah, D., Thase, M. E., et al. Efficacy of duloxetine on painful physical symptoms in depression: an integrated analysis of 11 clinical studies. J Affect Disord. 125(1\u20133), 53\u201360. https:\/\/doi.org\/10.1016\/j.jad.2009.12.021 (2010).","DOI":"10.1016\/j.jad.2009.12.021"},{"issue":"3","key":"27617_CR29","first-page":"138","volume":"8","author":"P Devi","year":"2015","unstructured":"Devi, P., Madhu, K. & Subrahmanyam, G. A prospective study of efficacy and safety of Pregabalin in neuropathic pain. Asian J. Pharm. Clin. Res. 8 (3), 138\u2013140 (2015).","journal-title":"Asian J. Pharm. Clin. Res."},{"issue":"1","key":"27617_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0304-3959(83)90125-9","volume":"17","author":"DD Price","year":"1983","unstructured":"Price, D. D., McGrath, P. A., Rafii, A. & Buckingham, B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17 (1), 45\u201356. https:\/\/doi.org\/10.1016\/0304-3959(83)90125-9 (1983).","journal-title":"Pain"},{"issue":"4","key":"27617_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1389-9457(01)00256-9","volume":"2","author":"CH Bastien","year":"2001","unstructured":"Bastien, C. H., Valli\u00e8res, A. & Morin, C. M. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep. Med. 2 (4), 297\u2013307. https:\/\/doi.org\/10.1016\/S1389-9457(01)00256-9 (2001).","journal-title":"Sleep. Med."},{"issue":"6","key":"27617_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 67 (6), 361\u2013370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x (1983).","journal-title":"Acta Psychiatr Scand."},{"key":"27617_CR33","unstructured":"GraphPad Prism version 9.0.0 for Windows. San Diego, CA: GraphPad Software. https:\/\/www.graphpad.com"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27617-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:36:40Z","timestamp":1765964200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27617-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43980"}}